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Background: Antipsychotic medications are the common treatment for schizophrenia. However, reliable
biomarkers that can predict individual treatment response are still lacking. The present study aimed to examine
whether baseline putamen activity can predict individual treatment response in schizophrenia.
Methods: Two independent samples of patients with drug-naive,ﬁrst-episode schizophrenia (32 patients in sam-
ple 1 and 44 in sample 2) and matched healthy controls underwent resting-state functional magnetic resonance
imaging (fMRI) at baseline. Patients were treated with olanzapine for 8 weeks; symptom severity was assessed
using the Positive and Negative Syndrome Scale (PANSS) at baseline andweek 8. Fractional amplitude of low fre-
quency ﬂuctuation (fALFF) and pattern classiﬁcation techniques were used to analyze the data.
Findings:Univariate analysis shows an elevatedpre-treatment fALFF in the left ventromedial putamen inboth pa-
tient samples compared to healthy controls (p's b 0.001). The support vector regression (SVR) analysis suggests a
positive relationship between baseline pre-treatment fALFF in the left ventromedial putamen and improvement
in positive symptom at week 8 in each patient group using a cross-validated method (r= 0.452, p= .002; r=
0.511, p= .003, respectively).
Interpretation:Our study suggests that elevated pre-treatmentmean fALFF in the left ventromedial putamenmay
predict individual therapeutic response to olanzapine treatment in drug-naive, ﬁrst-episode patients with
schizophrenia. Future studies are needed to conﬁrmwhether this ﬁnding is generalizable to patientswith schizo-
phrenia treated with other antipsychotic medications.
Fund: The National Key R&D Program of China and the National Natural Science Foundation of China.









Putamen, a key component of the striatum, receives afferent infor-
mation from cortical regions (i.e., the prefrontal cortex), and sends in-
formation back to cortical regions via thalamus [1]. Through the
cortico-striato-thalamo-cortical circuit, putamen plays a critical role in
themodulation and integration ofmotor, emotion,motivation, and cog-
nitive function [2–4].
Structural abnormalities and dysfunction of putamen might be in-
volved in schizophrenia [5,6]. For example, increased putamen size
was associated with decreased positive symptoms of schizophrenia
after six weeks of treatment [7]. In contrast, putamen shrinkage was
found in patients with schizophrenia who had never been exposed to
antipsychotic medications [8]. Reduced putamen size was observed in
patients who discontinued treatment, whereas increased putamen
size was found in patients with continued antipsychotic treatment in-
cluding olanzapine, quetiapine, and risperidone [9]. In addition, ele-
vated metabolism in putamen has been reported in patients with
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chronic schizophrenia who received antipsychotic treatment [10].
Furthermore, different antipsychotic drugs have different effects on pu-
tamen size. For example, exposure to quetiapinemight result in reduced
putamen density [11], whereas exposure to risperidone could lead to
putamen enlargement [12].
Given the potential role of putamen in schizophrenia and the fact
that antipsychotic treatment is associated with both structural and
functional changes in putamen, a clinically relevant key question
would be whether baseline pre-treatment putamen activity can serve
as a biomarker to predict therapeutic response in patients with schizo-
phrenia. To answer this question, several important confounding and/or
limiting factors, which often complicated the ﬁndings from previous
studies, must be addressed. For example, chronic and medicated pa-
tients were enrolled in many previous studies; it has been well
established that both disease duration and exposure to antipsychotic
treatmentmay have neurotoxic effect on the brain [13–18]. In addition,
previous studies often included patients whowere on different antipsy-
chotic agents, which may have differential effects on the brain [19,20].
Further, the imaging predictors explored previously were brain struc-
tural and functional alterations after antipsychotic therapy [7,21].
There is still lack of studies focusing on pre-treatment imaging predic-
tors, which are helpful for psychiatrists to make an informed decision
regarding the choice of antipsychotic medications before initiating a
treatment.
Many previous brain atlases are based on ex vivo histological atlases,
and lack of ﬁne-deﬁned parcellations to provide in vivo information
[22]. Recently, a connectivity-based brainnetome atlas became available
to offer a ﬁne-grained, cross-validated brain atlas [22]. According to this
new atlas, putamen is divided into four subregions: left/right ventrome-
dial putamen and left/right dorsolateral putamen. Hence, regional spe-
ciﬁc alterations of putamen can be explored in detail.
Most previous studies used univariate statistics to predict treatment
outcome at the group level [23],which is of little utility in everyday clin-
ical practice when psychiatrists need to make treatment decision at the
individual patient level. Pattern classiﬁcation techniques, such as sup-
port vector machine (SVM) and support vector regression (SVR),
allow predictions to be made at the individual level [24,25]. Such tech-
niques have been used to discriminate patients with adolescent-onset
schizophrenia from healthy controls [26–28], and to predict individual
response to electroconvulsive treatment in major depressive disorder
[29].
In most of previous clinical prediction studies, there was a lack of
validation of the predictive model in an independent patient sample.
Therefore, it remains unclear, to what extent, that the proposed predic-
tive model can be replicated and validated in patients other than the
single study sample.
In thepresent study,we recruited two independent samples of drug-
naive, ﬁrst-episode patients with schizophrenia from two different geo-
graphic locations in China. Functional magnetic resonance imaging
(fMRI) scans were obtained at baseline (prior to the initiation of anti-
psychotic treatment). Symptom severity was assessed at baseline and
after receiving 8 weeks of olanzapine treatment. Using the fractional
amplitude of low frequency ﬂuctuation (fALFF) method and pattern
classiﬁcation techniques including SVR, the present study was to exam-
ine the activity of putamen in drug-naive, ﬁrst-episode patients with
schizophrenia and its role in predicting individual therapeutic response
to olanzapine treatment. Hypothesis-driven and data-driven ap-
proacheswere used in the present study. Based on the abovementioned
studies, increased regional activity in putamen was expected to predict
individual therapeutic response to olanzapine treatment (hypothesis-
driven). The putamen was divided into four subregions: left/right
ventromedial putamen and left/right dorsolateral putamen. The data-
driven approach was used to determine which subregion with abnor-
mal activity in the two study samples was used to predict individual
therapeutic response to olanzapine treatment.
2. Materials and methods
2.1. Subjects
Sample 1 included 34 drug-naive, ﬁrst-episode patients with schizo-
phrenia and 34 healthy controls. Patients were recruited from the
Department of Psychiatry, the Second Xiangya Hospital of Central
South University in Hunan Province, China; healthy controls were re-
cruited from the local community. Sample 2 included 46 drug-naive,
ﬁrst-episode patients with schizophrenia and 46 healthy controls. Pa-
tients were recruited from the Mental Health Center, the Second
Research in context
Evidence before this study
We searched PubMed from the start of the database until April 1,
2019, for putamen activity to predict treatment response in
schizophrenia, with the search terms “schizophrenia”, “putamen”,
and “treatment response [Title]”, and “English” [Language]. We
found two published articles before we initiated the study. In
these studies, gray matter volume (GMV) was used to predict
treatment response in schizophrenia. One study demonstrated
that the caudate GMV changes after treatment were able to pre-
dict treatment response after 6 weeks of risperidone treatment.
The other study reported that an increased putamen GMVwas as-
sociatedwith decreased positive symptoms of schizophrenia after
six weeks of antipsychotic treatment. Several important con-
founding and/or limiting factors, such as long illness duration, pre-
vious exposure to antipsychotic medication, a gross brain atlas
used, prediction at the group level rather than individual patient
level, exploration of post-treatment predictors rather than pre-
treatment predictors, and lack of cross-validation of the predictive
model, may have complicated the findings from previous studies.
Added value of this study
The present study intended to answer a clinically relevant key
question: can baseline pre-treatment putamen activity serve as a
biomarker to predict therapeutic response in patients with
schizophrenia?
Two independent samples of patients with drug-naive, first-
episode schizophrenia (32 patients in sample 1 and 44 in sample
2) and matched healthy controls underwent resting-state func-
tional magnetic resonance imaging (fMRI) at baseline. The present
study aimed to examine the role of baseline pre-treatment puta-
men in predicting therapeutic response to olanzapine treatment
in two independent samples of patients with drug-naive, first-
episode schizophrenia using a combination of hypothesis-driven
and data-driven approaches. The support vector regression
(SVR) analysis suggests that baseline levels of fALFF in the left
ventromedial putamen can predict improvement in positive symp-
toms after 8 weeks of olanzapine treatment.
Implications of all the available evidence
First, the left ventromedial putamen activity may predict individual
therapeutic response to olanzapine treatment in drug-naive, first-
episode patients with schizophrenia. Second, the fact that the
findings were consistent across two independent study samples
cross-validates the predictive value of the left ventromedial puta-
men activity for antipsychotic treatment response. Finally, such
a pre-treatment predictor, if further confirmed, is helpful for psy-
chiatrists to make an informed decision regarding the choice of an-
tipsychotic medications when initiating treatment.
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Afﬁliated Hospital of Guangxi Medical University in Guangxi Province,
China; healthy controls were recruited from the local community.
Both patient and healthy controls were Han Chinese with the age
range 18–50 years old and right-handed, and had N6 years of formal ed-
ucation. Patients were diagnosed with schizophrenia according to the
Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV).
They were never treated with antipsychotic medications or other psy-
chotropic agents. The diagnosis of schizophrenia was further deter-
mined by two research psychiatrists (W.G. and Z.Z.) using the
Structural Clinical Interview for DSM-IV (SCID), patient version [30].
All patients had a Positive and Negative Syndrome Scale (PANSS) total
score of N70 at baseline. Exclusion criteria included history of alcohol
or other substanceuse, history of brain injury, or any ongoing signiﬁcant
medical conditions.
Healthy controls were recruited through advertisement. A complete
medical history, physical examination, and routine laboratory tests
were obtained for all healthy controls to rule out possible medical con-
ditions; in addition, the same research psychiatrists (W.G. and Z.Z.) con-
ducted a structured clinical interview using the SCID, non-patient
version [30] to rule out any psychiatric conditions. None of them had a
history of any psychiatric conditions, alcohol or substance use; further,
those who had a ﬁrst-degree relative diagnosed with psychiatric disor-
ders were also excluded from the study.
The study was reviewed and approved by the ethics committees of
the SecondXiangyaHospital of Central South University and the Second
Afﬁliated Hospital of Guangxi Medical University. A written informed
consent was obtained from each subject.
2.2. Procedure
After the screening visit, those individuals who ﬁt the inclusion and
exclusion criteria were enrolled in the study. All subjects went through
the brain MRI imaging scan and symptom severity was assessed using
the PANSS at baseline. Then patient subjects received olanzapine (10-
30mg/day as clinically appropriate and tolerated) for 8weeks. The clin-
ical symptoms were assessed again at week 8 using the PANSS.
2.3. Data acquisition and preprocessing
Imagining scans were acquired using 3 T MRI scanners (Siemens
Verio, Erlangen, Germany). The data were preprocessed using the
DPABI software [31]. The details of data acquisition and preprocessing
are provided in eMethods 1 in the Supplement.
2.4. fALFF
The fALFF method in our study is similar as used in a previous study
[32]. The details for fALFF calculation can be found in the Supplement.
After that, mean fALFF values in the subregions (left/right ventromedial
putamen and left/right dorsolateral putamen) of the putamen were ex-
tracted from each subject using masks (Fig. 1) from the human
brainnetome atlas (http://atlas.brainnetome.org) [22].
2.5. Statistical analyses
Analysis of variance (ANOVA), independent t-tests, and Chi-square
tests were employed to analyze demographic and clinical data across
groups as appropriate.
Analyses of covariance (ANCOVA) with Sample (sample 1, sample
2) and Diagnosis (patients, controls) as between subject factors control-
ling for potential confounding variables, were conducted to determine
the Sample × Diagnosis interactions for baseline pre-treatment fALFF
values in each subregion. Framewise displacement (FD) was calculated
for each subject according to a previous study [33]. The mean FD and
age served as covariates in the analyses. The signiﬁcance level was set
at p b .05.
If the Sample × Diagnosis interactions were not signiﬁcant, further
post hoc t-tests were used to compare group differences (patients ver-
sus controls) in baseline pre-treatment fALFF values in each subregion
averaging over both samples. The signiﬁcance level was set at p b .05.
To assess treatment outcome, the following formula was used to cal-
culate the reduction ratio (RR) of the PANSS total scores.
RR ¼ PANSStotal 0–PANSStotal 8wð Þ=PANSStotal 0
PANSStotal_0 refers to the PANSS total scores at baseline (pre-treat-
ment), whereas PANSStotal_8w is the PANSS total scores after 8 weeks
of olanzapine treatment. Similar RRs were calculated for the PANSS
Positive Symptoms, Negative Symptoms and General Psychopathology
subscale scores.
To test whether there were correlations in brain activity between
the left and right ventromedial/dorsolateral putamen, Pearson correla-
tion analyses were performed for fALFF values between the left and
right ventromedial/dorsolateral putamen within the groups.
Pearson correlation analyses were also conducted between the pre-
treatment fALFF values and pre-treatment PANSS scoreswithin each pa-
tient sample.
2.6. Pattern classiﬁcation analyses
The LIBSVM software (http://www.csie.ntu.edu.tw/~cjlin/libsvm/)
was used to performpattern classiﬁcation analysis. Once the subregions
with abnormal fALFF were identiﬁed in both patient samples, mean
fALFF values in such subregions were selected to run the SVR analyses
(data-driven). For each subregion and each symptom domains (the
PANSS total and Positive Symptoms, Negative Symptoms and General
Psychopathology subscale scores), SVR was conducted and cross-
validated with one sample as a train set and the other sample as a test
set. SVR was used to individually predict symptom improvement as
reﬂected by the RR. The SVR results were validated by a permutation
test, which ran 1000 times for each SVR result.
3. Results
3.1. Baseline characteristics of the subjects
Seven scans (2 patients and 1 control from Sample 1; 2 patients and
2 controls from Sample 2) were excluded due to excessive headmotion,
and one healthy control from Sample 1 withdrew the consent. Hence,
the ﬁnal samples included 32 patients and 32 controls in Sample 1
and 44 patients and 44 controls in Sample 2.
Between Sample 1 and Sample 2, no signiﬁcant differences were ob-
served gender (x2=1.825, p= .610), education (F=2.437, p= .067),
and FD (F= 0.424, p= .736). However, participants in Sample 1 were
older than individuals in Sample 2 (F = 18.986, p b .001). Patients in
Sample 1 had shorter illness duration (t = −8.553, p b .001), scored
less in the baseline PANSS Positive Symptoms subscale scores (t =
−2.151, p = .035), General Psychopathology subscale scores (t =
−7.242, p b .001) and total scores (t=−6.958, p b .001). There were
no signiﬁcant differences in dosage of olanzapine (t = 0.253, p =
.801) and the baseline PANSS Negative Symptoms scores (t=−1.671,
p= .099) for patients between the two samples.
Within each study sample, there were no signiﬁcant differences in
age, gender, education level and the mean FD values between patients
and healthy controls (p's N 0.250) (Table 1). The PANSS total score
and Positive Symptoms, Negative Symptoms and General Psychopa-
thology subscale scores for Sample 1 and Sample 2 are shown in Table 2.
3.2. Baseline group differences in fALFF
As shown in Table 3, the patient group in Sample 1 showed higher
levels of fALFF in bilateral ventromedial putamen and bilateral
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dorsolateral putamen compared to healthy controls. By contrast, the pa-
tient group in Sample 2 showed higher levels of fALFF in the left ventro-
medial putamen compared to the control group.
The ANCOVA controlling for themean FD and age revealed the Diag-
nosis Main Effects were signiﬁcant with t/p values 5.377/0.000, 2.911/
0.004, 2.866/0.005, and 2.568/0.011 for baseline pre-treatment fALFF
in the left ventromedial putamen, left dorsolateral putamen, right ven-
tromedial putamen, and right dorsolateral putamen, respectively.
No signiﬁcant Sample × Diagnosis interactions for baseline pre-
treatment fALFF in 3 subregions. The F/p values were 1.318/0.253,
0.580/0.447, and 1.919/0.168 in the left ventromedial putamen, left dor-
solateral putamen, and right dorsolateral putamen, respectively. How-
ever, the interaction was close to signiﬁcant for the right ventromedial
putamen with F/p values 3.718/0.052.
Based on these observations from the 2 separate study samples, fur-
ther prediction and pattern classiﬁcation analyses relating baseline
pre-treatment putamen activity to therapeutic response focused on
the following 3 subregions: the left ventromedial putamen, left and
right dorsolateral putamen.
3.3. Clinical symptoms after 8 weeks of olanzapine treatment
As shown in Table 2, after 8 weeks of olanzapine treatment, the pa-
tient group in Sample 1 showed signiﬁcant improvement in the PANSS
total score, Positive Symptoms, Negative Symptoms and General Psy-
chopathology subscale scores (36.50 ± 2.97, 8.91 ± 1.55, 8.97 ± 1.84,
18.63±1.48 respectively, mean±SD), compared to the baseline scores
(p's b 0.001); the patient group in Sample 2 also showed signiﬁcant
Fig. 1. The masks of four subregions of putamen generated from the brainnetome atlases (http://atlas.brainnetome.org). vmPu= ventromedial putamen, dlPu = dorsolateral putamen.
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improvement in the PANSS total score, Positive Symptoms, Negative
Symptoms and General Psychopathology subscale scores (38.70 ±
7.44, 7.50 ± 1.19, 9.50 ± 2.56, 21.70 ± 5.26, respectively, mean ±
SD), compared to the baseline scores (p's b 0.001).
3.4. Correlation results
As shown in Table S1, signiﬁcant correlationswere observed for pre-
treatment fALFF values between the left and right ventromedial/dorso-
lateral putamenwithin the groups (ps b 0.001) except the pair of the left
and right ventromedial putamen in the controls of Sample 2 (p= .073).
In addition, there were no signiﬁcant correlations between pre-
treatment fALFF values and pre-treatment PANSS total or subscale
scores within each patient group.
3.5. Pattern classiﬁcation results
To test whether pre-treatment fALFF in the left ventromedial puta-
men can predict therapeutic response after 8 weeks of olanzapine treat-
ment, SVR was conducted and cross-validated with one sample as a
train set and the other sample as a test set.
When Sample 1 was used as a train set and Sample 2 used as a test
set, the SVR analysis showed a signiﬁcantly positive relationship be-
tween pre-treatment levels of fALFF in the left ventromedial putamen
and week 8 RR values of the PANSS Positive Symptoms subscale scores
(r= 0.452, p= .002, Fig. 2). The permutation test showed a p value of
0.0020 for this SVR result. No signiﬁcant correlationswere observed be-
tween pre-treatment levels of fALFF in the left ventromedial putamen
and week 8 RR values of other PANSS scores.
When Sample 2 was used as a train set and Sample 1 used as a test
set, the SVR analysis also showed a signiﬁcantly positive relationship
between pre-treatment levels of fALFF in the left ventromedial putamen
and week 8 RR values of the PANSS Positive Symptoms subscale scores
(r = 0.511, p = .003, Fig. 3). For this SVR result, the permutation test
showed a p value of 0.0143. There were no signiﬁcant correlations be-
tween pre-treatment levels of fALFF in the left ventromedial putamen
and week 8 RR values of other PANSS scores.
Similarly, SVR analyseswere conducted for the left/right dorsolateral
putamen with one sample as a train set and the other sample as a test
set. When Sample 1 was used as a train set and Sample 2 used as a
test set, the SVR analysis showed no signiﬁcant correlations between
pre-treatment levels of fALFF in the left/right dorsolateral putamen
and week 8 RR values of the PANSS Positive Symptoms subscale scores
(left dorsolateral putamen: r=0.115, p= .458, eFigure 1 in the Supple-
ment; right dorsolateral putamen: r=0.042, p= .790, eFigure 2 in the
Supplement). Further, there were also no signiﬁcant correlations be-
tween pre-treatment levels of fALFF in the left/right dorsolateral puta-
men and week 8 RR values of the PANSS Positive Symptoms subscale
scores in patients of Sample 1 when Sample 2 was used as a train set
and Sample 1 used as a test set (left dorsolateral putamen: r =
−0.095, p= .604, eFigure 3 in the Supplement; right dorsolateral puta-
men: r=−0.115, p=.532, eFigure 4 in the Supplement). No signiﬁcant
correlations were observed between pre-treatment levels of fALFF in
the left/right dorsolateral putamen and week 8 RR values of other
PANSS scores with one sample as a train set and another sample as a
test set.
4. Discussion
As far as we are aware of, the present study was the ﬁrst study to
examine the role of putamen in predicting therapeutic response to
olanzapine treatment in two independent samples of patients
with drug-naive, ﬁrst-episode schizophrenia using a combination of
hypothesis-driven and data-driven approaches. The SVR analysis sug-
gests that baseline pre-treatment levels of fALFF in the left ventromedial
putamen can predict positive symptom improvement after 8 weeks
olanzapine treatment.
Our ﬁndings are consistent with a previous study reporting that the
volume increase in putamenwas associatedwith positive symptom im-
provement asmeasured by theRR of the PANSS Positive Symptoms sub-
scale scores in drug-naive patientswith schizophrenia after sixweeks of
antipsychotic treatment [7]. Our ﬁndings are also in line with a previous
report that the volume increase in putamen was associated with a bet-
ter outcome in schizophrenia [23]; in that study, the authors suggested
that putamen enlargement may be an imaging marker of responsive-
ness to antipsychotic treatment. Similar ﬁndings were observed in an-
other study as well [34]. Since patients in the present study were
drug-naive when they underwent the imaging assessment, the activity
in the left ventromedial putamen measured in our study might be an
illness-related biomarker to predict therapeutic response.
The ventromedial putamen communicates with the ventromedial
thalamus, frontal cortex (the cortico-striato-thalamo-cortical circuit),
and insula through multi-ﬁber pathways [7]. The ventromedial
Table 1
Baseline demographic and clinical characteristics of the study participants.
Patients Healthy controls p value
Sample 1 N= 32 N = 32
Gender (male/female) 16/16 17/15 0.80
Age (years) 30.94 ± 8.25 30.47 ± 7.69 0.81
Education (years) 12.13 ± 3.19 12.41 ± 2.47 0.70
FD (mm) 0.03 ± 0.02 0.04 ± 0.03 0.26
Illness duration (months) 8.91 ± 6.39
Dosage of olanzapine (mg/d) 18.59 ± 4.96
Sample 2 N= 44 N = 44 p value
Gender (male/female) 28/16 23/21 0.28
Age (years) 23.45 ± 4.24 23.55 ± 2.58 0.90
Education (years) 11.11 ± 2.46 11.30 ± 1.67 0.69
FD (mm) 0.03 ± 0.03 0.03 ± 0.02 0.91
Illness duration (months) 22.34 ± 7.01
Dosage of olanzapine (mg/d) 18.30 ± 5.17
FD= framewise displacement; values are expressed as mean ± SD.
Table 2
The PANSS scores for patients at baseline and week 8.
PANSS Baseline Week 8 p value
Sample 1 (N = 32)
Positive symptoms 20.00 ± 4.32 8.91 ± 1.55 b0.001
Negative symptoms 20.59 ± 3.46 8.97 ± 1.84 b0.001
General psychopathology 36.78 ± 3.68 18.63 ± 1.48 b0.001
Total score 77.38 ± 5.17 36.50 ± 2.97 b0.001
Sample 2 (N = 44)
Positive symptoms 22.48 ± 5.37 7.50 ± 1.19 b0.001
Negative symptoms 22.50 ± 6.38 9.50 ± 2.56 b0.001
General psychopathology 45.73 ± 6.97 21.70 ± 5.26 b0.001
Total score 90.70 ± 11.17 38.70 ± 7.44 b0.001
PANSS= the Positive and Negative Syndrome Scale; values are expressed as mean ± SD.
Table 3
Baseline group comparison in levels of fALFF in different subregions of putamen.
Subregions of putamen Patients Healthy controls p value
Sample 1 N = 32 N = 32
Left ventromedial putamen 0.0231 ± 0.0747 −0.0477 ± 0.0650 b0.001
Left dorsolateral putamen −0.0246 ± 0.0859 −0.0673 ± 0.0545 0.021
Right ventromedial putamen 0.0077 ± 0.0690 −0.0504 ± 0.0565 b0.001
Right dorsolateral putamen −0.0123 ± 0.0873 −0.0594 ± 0.0613 0.015
Sample 2 N = 44 N = 44
Left ventromedial putamen −0.0004 ± 0.0636 −0.0464 ± 0.0566 0.001
Left dorsolateral putamen −0.0371 ± 0.0680 −0.0618 ± 0.0634 0.082
Right ventromedial putamen −0.0529 ± 0.0781 −0.0662 ± 0.0647 0.386
Right dorsolateral putamen −0.0577 ± 0.0656 −0.0732 ± 0.0606 0.252
fALFF = fractional amplitude of low frequency ﬂuctuation; values are expressed as mean
± SD.
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putamen plays a central role in the integration andmodulation of many
motor, higher-level cognitive, and limbic processes [3]. Furthermore,
the ventromedial putamen is rich in dopamine, a main neurotransmit-
ter in complex behavioral and cognitive symptoms [35]. According
to the dopamine hypothesis, positive symptoms are thought to
result from enhanced dopamine in the subcortical regions, such as the
ventromedial putamen [36]. Consistent with the dopamine hypothesis,
we found increased pre-treatment activity in the left ventromedial
putamen in patients in each of the two study samples, which
positively correlated with the RR of the PANSS Positive Symptoms sub-
scale scores after 8 weeks of olanzapine treatment. The left ventrome-
dial putamen could potentially be a treatment target in future drug
development.
Signiﬁcant correlations were observed for fALFF values between the
left and right ventromedial putamen. However, only the left ventrome-
dial putamen, not the right ventromedial putamen, showed predictive
value for positive symptom improvement after 8 weeks of olanzapine
treatment. In our study, patients in both study samples showed elevated
pre-treatment levels of fALFF in the left ventromedial putamen, but not
in the right ventromedial putamen. As hypothesized by the data-driven
method, the fact that no signiﬁcant elevation of fALFF in the right ven-
tromedial putamen in thepatients of Sample 2might prohibit its predic-
tive role for treatment response. We also tested the predictive value of
fALFF in the left/right dorsolateral putamen using the SVR method. No
signiﬁcant relationships were found between pre-treatment levels of
fALFF in the left/right dorsolateral putamen and week 8 RR values of
the PANSS total or subscale scoreswith one sample as a train set and an-
other sample as a test set.
Our ﬁndings are consistent with a previous report [23], which
showed an increased left putamen volume in those with a better out-
come in patients with chronic schizophrenia. In addition, our ﬁndings
are in line with the results from another study that reported a correla-
tion between a larger size in the left ventral putamen and less severe
paranoid symptoms in individuals with schizotypal personality disor-
der, and individuals with a larger size in the left ventral putamen
responded better to antipsychotic treatment [37].
Fig. 2. SVR results suggest that higher levels of fALFF in the left ventromedial putamen predict therapeutic response in patients in Sample 2 using Sample 1 as a train set and Sample 2 as a
test set. Left: SVR parameters selection results (3D visualization); Right: A positive correlation between predicted and actual RRs of the PANSS Positive Symptoms subscale scores of
individual patients after 8 weeks of olanzapine treatment (r = 0.452, p= .002). SVR = support vector regression; fALFF = fractional amplitude of low frequency ﬂuctuation; PANSS
= the Positive and Negative Syndrome Scale; RR = reduction rate.
Fig. 3. SVR results suggest that higher levels of fALFF in the left ventromedial putamen predicts therapeutic response in patients in Sample 1 using Sample 2 as a train set and Sample 1 as a
test set. Left: SVR parameters selection results (3D visualization); Right: A positive correlation between predicted and actual RRs of the PANSS Positive Symptoms subscale scores of
individual patients after 8 weeks of olanzapine treatment (r = 0.511, p= .003). SVR = support vector regression; fALFF = fractional amplitude of low frequency ﬂuctuation; PANSS
= the Positive and Negative Syndrome Scale; RR = reduction rate.
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There are several novel aspects in the present study. First, drug-
naive, ﬁrst-episode patients with schizophrenia were enrolled in each
study sample, minimizing important potential confounding factors
such as prior exposure to antipsychotic medications and chronicity of
illness. Second, SVR was employed to predict treatment response in
schizophrenia. Compared with traditional univariate analysis, pattern
classiﬁcation techniques can individually classify patients with good
response from those with poor response. Hence, the established pre-
treatment predictor can help psychiatrists make an informed, individu-
alized decision on the choice of antipsychotic medications when initiat-
ing a treatment. Third, two independent study samples were recruited
in the present study. The fact that the ﬁndings were consistent across
the two samples cross-validates the predictive value of the left ventro-
medial putamen activity for antipsychotic treatment response. Finally,
a humanbrainnetome atlaswas employed in the present study to divide
putamen into four subregions: left/right ventromedial putamen and
left/right dorsolateral putamen; this allows the data to be processed
with ﬁne-grained parcellations [22].
In addition to a relatively small study sample size, the present study
has several limitations. First, olanzapine monotherapy was used in our
study. It is helpful tominimize the confounding effect caused by different
antipsychotic medications. However, it is unclear whether our ﬁndings
are generalizable to patients treated with other antipsychotic medica-
tions as differentmedicationsmayhavedifferential effects onbrain activ-
ity [19,20]. Second, it is unclearwhether ourﬁndings are generalizable to
chronic patients with schizophrenia who have been exposed to various
antipsychoticmedications, and/or have co-occurring substanceuse prob-
lems. Third, patients in Sample 1 and Sample 2 did not match in several
demographic and clinical variables, which might limit the comparisons
in outcome measures between Sample 1 and Sample 2. However, such
differencesmay increase the generalizability of the present ﬁndings con-
sidering that schizophrenia is a highly heterogenous disease.
In conclusion, our study suggests that elevated pre-treatment mean
fALFF in the left ventromedial putamen may predict better individual
therapeutic response in positive symptoms to olanzapine treatment in
drug-naive, ﬁrst-episode patients with schizophrenia. Larger-scale fu-
ture studies to further examine the clinical utility of using putamen ac-
tivity as a biomarker to predict treatment response in real world
patients with schizophrenia are warranted.
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